INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 44h ago
House PTR4h ago
SEC 13F4h ago
Robinhood Chain4h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 150S150 trades$600K
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SJSheena Jonathan0B / 45S45 trades$3.01M
  8. 08SISarowitz Steven I2B / 34S36 trades$22.46M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,500 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
Page 1477 of 1813
← PrevNext →
traded Jan 12, 2026
+2d
SEC Form 4

Evidence

36
NR
Neale Erin RoseSVP, Chief Legal Officer
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$40K
2,257 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$2,235
6 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$387K
4,240 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MM
Mangione Christopher MichaelChief Acct. Off. & VP, Finance
SNCYSun Country Airlines Holdings, Inc.
Open-market sale
SELL$4,489
256 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$32K
87 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$44K
123 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$467K
5,181 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$28K
78 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$44K
123 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
42 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
34 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$27K
76 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,047
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$10K
27 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$13K
36 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
42 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
PV
Poulton Jeffrey V.EVP, Chief Financial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$49K
135 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$467K
5,182 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
TT
Tanguler TolgaEVP, Chief Commercial Officer
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

36
GP
Garg PushkalEVP Chief R&D
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence